with Merck & Co-partnered melanoma vaccine mRNA-4157 heading for a pivotal phase 3 programme after a phase 2b data drop at ASCO. In the study, mRNA-4157 (V940) – which targets dozens of unique ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback